Selective identification of secreted and transmembrane breast cancer markers using Escherichia coli ampicillin secretion trap

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8209-8217

  Ferguson, Deborah A ^a   Muenster, Matthew R ^a   Zang, Qun ^a   Spencer, Jeffrey A ^a   Schageman, Jeoffrey J ^a   Lian, Yun ^a   Garner, Harold R ^a   Gaynor, Richard B ^a   Huff, J Warren ^c   Pertsemlidis, Alexander ^a   Ashfaq, Raheela ^b   Schorge, John ^b   Becerra, Carlos ^a   Williams, Noelle S ^b   Graff, Jonathan M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Reata Discovery Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CELL SURFACE PROTEIN; COMPLEMENTARY DNA; SIGNAL PEPTIDE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA LIBRARY; DRUG TARGETING; EMBRYO; ESCHERICHIA COLI; ESCHERICHIA COLI AMPICILLIN SECRETION TRAP; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PENICILLIN RESISTANCE; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; UNINDEXED SEQUENCE;

AMPICILLIN RESISTANCE; BETA-LACTAMASES; BREAST NEOPLASMS; ESCHERICHIA COLI; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PLASMIDS; PROTEIN SORTING SIGNALS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 24944552907     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3726     Document Type: Article

References (48)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992;13:3-17.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
4. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-7.
5. Sledge GW Jr. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002;29:104-10.
6. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-91.
7. Brandt R, Eisenbrandt R, Leenders F, et al. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 2000;19:2129-37.
8. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000;60:3081-7.
9. Nahta R, Hortobagyi GN, Estera FJ. Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 2003;8:5-17.
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
11. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefltinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-6.
12. Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 2003;30:34-46.
13. Sledge GW, Miller KD. Exploiting the hallmarks of cancer. The future conquest of breast cancer. Eur J Cancer 2003;39:1668-75.
14. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T. Signal sequence trap: a cloning strategy for secreted proteins and type 1 membrane proteins. Science 1993;261:600-3.
15. Klein RD, Gu Q, Goddard A, Rosenthal A. Selection for genes encoding secreted proteins and receptors. Proc Natl Acad Sci U S A 1996;93:7108-13.
16. Kojima T, Kitamura T. A signal sequence trap based on a constitutively active cytokine receptor. Nat Biotechnol 1999;17:487-90.
17. Lim SP, Garzino-Demo A. Cloning trap for signal peptide sequences. Biotechniques 2000;28:124-6, 128-30.
18. Mechler BM. Isolation of messenger RNA from membrane-bound polysomes. Methods Enzymol 1987;152:241-8.
19. Diehn M, Eisen MB, Botstein D, Brown PO. Large-scale identification of secreted and membrane-associated gene products using DNA microarrays. Nat Genet 2000;25:58-62.
20. Nielsen H, Brunak S, von Heijne G. Machine learning approaches for the prediction of signal peptides and other protein sorting signals. Protein Eng 1999;12:3-9.
21. Adam PJ, Boyd R, Tyson KL, et al. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem 2003;278:6482-9.
22. von Heijne G. A new method for predicting signal sequence cleavage sites. Nucleic Acids Res 1986;14:4683-90.
23. Schnell DJ, Hebert DN. Protein translocons: multifunctional mediators of protein translocation across membranes. Cell 2003;112:491-505.
24. Kadonaga JT, Gautier AE, Straus DR, Charles AD, Edge MD, Knowles JR. The role of the β-lactamase signal sequence in the secretion of proteins by Escherichia coli. J Biol Chem 1984;259:2149-54.
25. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-99.
26. Colomer R, Shamon LA, Tsai MS, Lupu R. Herceptin: from the bench to the clinic. Cancer Invest 2001;19:49-56.
27. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-10.
28. Schuler GD, Boguski MS, Stewart EA, et al. A gene map of the human genome. Science 1996;274:540-6.
29. Nakai K, Kanehisa M. A knowledge base for predicting protein localization sites in eukaryotic cells. Genomics 1992;14:897-911.
30. Schultz J, Milpetz F, Bork P, Ponting CP. SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci U S A 1998;95:5857-64.
31. Nielsen H, Engelbrecht J, Brunak S, von Heijne G. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng 1997;10:1-6.
32. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-86.
33. Korkmaz KS, Elbi C, Korkmaz CG, Loda M, Hager GL, Saatcioglu F. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem 2002;277:36689-96.
34. Moog-Lutz C, Cave-Riant F, Guibal FC, et al. JAML, a novel protein with characteristics of a junctional adhesion molecule, is induced during differentiation of myeloid leukemia cells. Blood 2003;102:3371-8.
35. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9.
36. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
37. Tanimoto H, Yan Y, Clarke J, et al. a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 1997;57:2884-7.
38. Zacharski LR, Ornstein DL, Memoli VA, Rousseau SM, Kisiel W. Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma. Thromb Haemost 1998;79:876-7.
39. Feinberg EH, Hunter CP. Transport of dsRNA into cells by the transmembrane protein SID-1. Science 2003;301:1545-7.
40. Winston WM, Molodowitch C, Hunter CP. Systemic RNAi in C elegans requires the putative transmembrane protein SID-1. Science 2002;295:2456-9.
41. Berois N, Varangot M, Sonora C, et al. Detection of bone marrow-disseminated breast cancer cells using an RT-PCR assay of MUC5B mRNA. Int J Cancer 2003;103:550-5.
42. Hur EM, Son M, Lee OH, et al. LIME, a novel transmembrane adaptor protein, associates with p561ck and mediates T cell activation. J Exp Med 2003;198:1463-73.
43. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002;161:1215-21.
44. Warman ML, Abbott M, Apte SS, et al. A type X collagen mutation causes Schmid metaphyseal chondrodysplasia. Nat Genet 1993;5:79-82.
45. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348:2339-47.
46. Jones C, Mackay A, Grigoriadis A, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 2004;64:3037-45.
47. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A 1989;86:9193-7.
48. Tan R, Jiang X, Jackson A, et al. E. coli selection of human genes encoding secreted and membrane proteins based on cDNA fusions to a leaderless β-lactamase reporter. Genome Res 2003;13:1938-43.